keyword
MENU ▼
Read by QxMD icon Read
search

Pca3

keyword
https://www.readbyqxmd.com/read/29115578/characterization-of-prostate-cancer-cell-progression-in-zebrafish-xenograft-model
#1
Wei Xu, Brittany A Foster, Mackenzie Richards, Kenneth R Bondioli, Girish Shah, Christopher C Green
Early diagnosis of prostate cancer (PCa) is critical for the application of efficient treatment to PCa patients. However, the majority of PCas remains indolent from several months to several years before malignancy. Current diagnosis methods have limitations in their reliability and are inefficient in time cost. Thus, an efficient in vivo PCa cell xenograft model is highly desired for diagnostic studies in PCas. In the present study we present a standardized procedure to create a PCa cell xenograft model using zebrafish (Danio rerio) as the host...
November 6, 2017: International Journal of Oncology
https://www.readbyqxmd.com/read/29107268/whom-to-biopsy-prediagnostic-risk-stratification-with-biomarkers-nomograms-and-risk-calculators
#2
REVIEW
Stacy Loeb, Hasan Dani
This article describes markers used for prostate biopsy decisions, including prostrate-specific antigen (PSA), free PSA, the prostate health index, 4Kscore, PCA3, and ConfirmMDx. It also summarizes the use of nomograms combining multiple variables for prostate cancer detection.
November 2017: Urologic Clinics of North America
https://www.readbyqxmd.com/read/29104903/biomarkers-for-prostate-biopsy-and-risk-stratification-of-newly-diagnosed-prostate-cancer-patients
#3
Stacy Loeb
Introduction: Many new markers are now available as an aid for decisions about prostate biopsy for men without prostate cancer, and/or to improve risk stratification for men with newly diagnosed prostate cancer. Methods: A literature review was performed on currently available markers for use in decisions about prostate biopsy and initial prostate cancer treatment. Results: Although total prostate-specific antigen cutoffs were traditionally used for biopsy decisions, PSA elevations are not specific...
July 2017: Urology Practice
https://www.readbyqxmd.com/read/29037514/re-association-between-combined-tmprss2-erg-and-pca3-rna-urinary-testing-and-detection-of-aggressive-prostate-cancer
#4
David G McLeod, Gyorgy Petrovics
No abstract text is available yet for this article.
October 13, 2017: European Urology
https://www.readbyqxmd.com/read/28972698/prognostic-value-of-urinary-pca3-during-active-surveillance-of-low-risk-prostate-cancer-in-patients-receiving-5%C3%AE-reductase-inhibitors
#5
Vincent Fradet, Paul Toren, Molière Nguile-Makao, Michele Lodde, Jérome Lévesque, Caroline Léger, André Caron, Alain Bergeron, Tal Ben-Zvi, Louis Lacombe, Frédéric Pouliot, Rabi Tiguert, Thierry Dujardin, Yves Fradet
OBJECTIVES: To determine the clinical performance of the urinary PCA3 test to predict the risk of Gleason grade re-classification among men receiving a 5α-reductase inhibitor during active surveillance for prostate cancer. PATIENTS AND METHODS: Patients with low-risk prostate cancer were enrolled in a prospective Phase II study of active surveillance complemented with prescription of a 5ARI. Repeat biopsy was performed within the first year and annually according to physician and patient preference...
October 3, 2017: BJU International
https://www.readbyqxmd.com/read/28938580/diagnostic-significance-of-urinary-long-non-coding-pca3-rna-in-prostate-cancer
#6
Tao Wang, Xiangyun Qu, Jiajia Jiang, Peng Gao, Dingding Zhao, Xueqi Lian, Xiaohua Li
Prostate cancer antigen 3(PCA3) is a long non-coding RNA, which was found increased expression in CaP patients than healthy individual. In this study, the individual nucleic acid of PCA3 and PSA was recombinant expressed as a reference reagent, and a quantitative RT-PCR with TaqMan assay was developed to examine the copies of PCA3 and PSA gene in urine. The results showed that the area under the receiver operating characteristic curve (AUROC) was 0.717, 0.444 and 0.916 for the number of PCA3 copy, PSA copy and for the score of PCA3/PSA RNA, respectively...
August 29, 2017: Oncotarget
https://www.readbyqxmd.com/read/28917266/urinary-biomarkers-in-prostate-cancer-detection-and-monitoring-progression
#7
REVIEW
Duojia Wu, Jie Ni, Julia Beretov, Paul Cozzi, Mark Willcox, Valerie Wasinger, Bradley Walsh, Peter Graham, Yong Li
Prostate cancer (CaP) is the most common cancer in men and the second leading cause of cancer deaths in males in Australia. Although serum prostate-specific antigen (PSA) has been the most widely used biomarker in CaP detection for decades, PSA screening has limitations such as low specificity and potential association with over-diagnosis. Current biomarkers used in the clinic are not useful for the early detection of CaP, or monitoring its progression, and have limited value in predicting response to treatment...
October 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/28881605/low-pca3-expression-is-a-marker-of-poor-differentiation-in-localized-prostate-tumors-exploratory-analysis-from-12-076-patients
#8
Mohammed Alshalalfa, Gerald W Verhaegh, Ewan A Gibb, Maria Santiago-Jiménez, Nicholas Erho, Jennifer Jordan, Kasra Yousefi, Lucia L C Lam, Tyler Kolisnik, Jijumon Chelissery, Roland Seiler, Ashley E Ross, R Jeffrey Karnes, Edward M Schaeffer, Tamara T Lotan, Robert B Den, Stephen J Freedland, Elai Davicioni, Eric A Klein, Jack A Schalken
BACKGROUND: Prostate cancer antigen 3 (PCA3) is a prostate cancer diagnostic biomarker that has been clinically validated. The limitations of the diagnostic role of PCA3 in initial biopsy and the prognostic role are not well established. Here, we elucidate the limitations of tissue PCA3 to predict high grade tumors in initial biopsy. RESULTS: PCA3 has a bimodal distribution in both biopsy and radical prostatectomy (RP) tissues, where low PCA3 expression was significantly associated with high grade disease (p<0...
August 1, 2017: Oncotarget
https://www.readbyqxmd.com/read/28864116/the-role-of-long-non-coding-rna-pca3-in-epithelial-ovarian-carcinoma-tumorigenesis-and-progression
#9
Yao Liu, Zhi-Hong Zong, Xue Guan, Li-Li Wang, Yang Zhao
OBJECTIVES: Ovarian carcinoma is one of the highest incidence of tumors in women, and the generation, development and prognosis of epithelial ovarian carcinoma (EOC) remains an open field of study. The role of long non-coding RNAs (lncRNAs) in epithelial ovarian carcinoma is an emerging area of research. MATERIALS AND METHODS: LncRNA PCA3 expression was determined in EOC and normal ovarian tissues by RT-PCR. Phenotypes indicative of tumor progression and aggressiveness, including cell proliferation, migration, invasion, and expression of related molecules, were analysed in EOC cell following knockdown of lncRNA PCA3 by transfection with small interfering RNA (siRNA)...
October 30, 2017: Gene
https://www.readbyqxmd.com/read/28861591/multianalyte-quantitative-competitive-pcr-on-optically-encoded-microspheres-for-an-eight-gene-panel-related-to-prostate-cancer
#10
Iraklis K Kyriakou, Konstantinos Mavridis, Despina P Kalogianni, Theodore K Christopoulos, Penelope C Ioannou, Andreas Scorilas
Nucleic acid-based tests have a profound impact in every medical discipline. Because multigene tests offer higher diagnostic accuracy and lower overall cost than single assays, they are especially useful for diseases, like prostate cancer, that present variability at the molecular level and diversity of available therapeutic interventions. We have developed a quantitative competitive PCR for an eight-gene panel, related to prostate cancer, that includes five genes of the human tissue kallikrein family (KLKs), prostate-specific membrane antigen (PSMA), prostate cancer antigen 3 (PCA3), and HPRT1 as a reference gene...
August 31, 2017: Analytical and Bioanalytical Chemistry
https://www.readbyqxmd.com/read/28853167/a-urinary-biomarker-based-risk-score-correlates-with-multiparametric-mri-for-prostate-cancer-detection
#11
Rianne J Hendriks, Marloes M G van der Leest, Siebren Dijkstra, Jelle O Barentsz, Wim Van Criekinge, Christina A Hulsbergen-van de Kaa, Jack A Schalken, Peter F A Mulders, Inge M van Oort
BACKGROUND: Prostate cancer (PCa) diagnostics would greatly benefit from more accurate, non-invasive techniques for the detection of clinically significant disease, leading to a reduction of over-diagnosis and over-treatment. The aim of this study was to determine the association between a novel urinary biomarker-based risk score (SelectMDx), multiparametric MRI (mpMRI) outcomes, and biopsy results for PCa detection. METHODS: This retrospective observational study used data from the validation study of the SelectMDx score, in which urine was collected after digital rectal examination from men undergoing prostate biopsies...
October 2017: Prostate
https://www.readbyqxmd.com/read/28807541/urinary-rna-based-biomarkers-for-prostate-cancer-detection
#12
REVIEW
Filippo Martignano, Lorena Rossi, Antonio Maugeri, Valentina Gallà, Vincenza Conteduca, Ugo De Giorgi, Valentina Casadio, Giuseppe Schepisi
Prostate cancer (PCa) is the commonest malignancy in the male population worldwide. Serum prostate specific antigen (PSA) test is the most important biomarker for the detection, follow-up and therapeutic monitoring of PCa. Defects in PSA specificity have elicited research for new biomarkers to improve early diagnosis and avoid false-positive results. This review evaluates urinary RNA-based biomarkers. Urine is a versatile body fluid for non-invasive biomarker detection in case of urological malignancies. The importance of RNA-based biomarkers has been demonstrated by the current use of PCA3, a long non coding RNA biomarker already approved by the Food and Drugs Administration...
October 2017: Clinica Chimica Acta; International Journal of Clinical Chemistry
https://www.readbyqxmd.com/read/28751581/going-viral-linking-the-etiology-of-human-prostate-cancer-to-the-pca3-long-noncoding-rna-and-oncogenic-viruses
#13
Andre A Teixeira, Serena Marchiò, Emmanuel Dias-Neto, Diana N Nunes, Israel T da Silva, Bryce Chackerian, Marc Barry, Richard C Lauer, Ricardo J Giordano, Richard L Sidman, Cosette M Wheeler, Webster K Cavenee, Renata Pasqualini, Wadih Arap
No abstract text is available yet for this article.
October 2017: EMBO Molecular Medicine
https://www.readbyqxmd.com/read/28739722/grp78-participates-in-pca3-regulated-prostate-cancer-progression
#14
Chunhua Lin, Jiahui Wang, Yanwei Wang, Peng Zhu, Xin Liu, Ning Li, Juan Liu, Luxin Yu, Wenting Wang
BACKGROUND/AIM: The human prostate cancer antigen 3 (PCA3) is a long non-coding RNA (lncRNA) commonly used as a diagnostic marker for prostate cancer (PCa). Herein we investigated the cellular function of PCA3 in PCa and its potential mechanism. MATERIALS AND METHODS: PCA3 was overexpressed in a PC3 cell line (PC3(PCA+)) and cell proliferation, migration, invasion and apoptosis were compared to those of control cells (PC3(NC)). Differentially expressed proteins were identified by two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) and mass spectrometry...
August 2017: Anticancer Research
https://www.readbyqxmd.com/read/28668854/pca3-silencing-sensitizes-prostate-cancer-cells-to-enzalutamide-mediated-androgen-receptor-blockade
#15
Emre Özgür, Ayca Iribas Celik, Emin Darendeliler, Ugur Gezer
BACKGROUND/AIM: Prostate cancer (PCa) is an androgen-dependent disease. Novel anti-androgens (i.e. enzalutamide) have recently been developed for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC). Evidence is accumulating that prostate cancer antigen 3 (PCA3) is involved in androgen receptor (AR) signaling. Here, in combination with enzalutamide-mediated AR blockade, we investigated the effect of PCA3 targeting on the viability of PCa cells. MATERIALS AND METHODS: In hormone-sensitive LNCaP cells, AR-overexpressing LNCaP-AR(+) cells and VCaP cells (representing CRPC), PCA3 was silenced using siRNA oligonucleotides...
July 2017: Anticancer Research
https://www.readbyqxmd.com/read/28552819/prostate-cancer-antigen-3-score-does-not-predict-for-adverse-pathologic-features-at-radical-prostatectomy-or-for-progression-free-survival-in-clinically-localized-intermediate-and-high-risk-prostate-cancer
#16
John V Hegde, Darlene Veruttipong, Jonathan W Said, Robert E Reiter, Michael L Steinberg, Christopher R King, Amar U Kishan
OBJECTIVE: To evaluate whether preoperative urinary prostate cancer antigen 3 (PCA3) scores predict for adverse pathologic features (APFs) or progression-free survival (PFS) in men with intermediate- or high-risk prostate cancer (PCa) undergoing radical prostatectomy (RP). MATERIALS AND METHODS: One hundred nine men with intermediate- (n = 52) or high-risk (n = 57) PCa who underwent RP were retrospectively identified. Logistic regression analysis was performed to evaluate the association of PCA3 score with various APFs (eg, extracapsular extension, seminal vesicle invasion, etc...
May 25, 2017: Urology
https://www.readbyqxmd.com/read/28524004/urinary-biomarkers-for-prostate-cancer
#17
Francesca Giunchi, Chiara Ciccarese, Rodolfo Montironi, Marina Scarpelli, Antonio Lopez-Beltran, Liang Cheng, Holger Moch, Francesco Massari, Michelangelo Fiorentino
Urine may represent a convenient source of biomarkers for the early detection of prostate cancer (PCa) since contains secreted prostatic products and exfoliated tumor cells. Furthermore urine are easy to collect with non-invasive procedures and they are repeatable. Several urinary biomarkers for PCa have been proposed in the past but only one (PCA3) has been approved for clinical use and even this is not widely utilized in the routine practice. Most of these, particularly the proteins, were abandoned due to lack of confirmation...
May 18, 2017: Current Drug Metabolism
https://www.readbyqxmd.com/read/28520829/association-between-combined-tmprss2-erg-and-pca3-rna-urinary-testing-and-detection-of-aggressive-prostate-cancer
#18
Martin G Sanda, Ziding Feng, David H Howard, Scott A Tomlins, Lori J Sokoll, Daniel W Chan, Meredith M Regan, Jack Groskopf, Jonathan Chipman, Dattatraya H Patil, Simpa S Salami, Douglas S Scherr, Jacob Kagan, Sudhir Srivastava, Ian M Thompson, Javed Siddiqui, Jing Fan, Aron Y Joon, Leonidas E Bantis, Mark A Rubin, Arul M Chinnayian, John T Wei, Mohamed Bidair, Adam Kibel, Daniel W Lin, Yair Lotan, Alan Partin, Samir Taneja
Importance: Potential survival benefits from treating aggressive (Gleason score, ≥7) early-stage prostate cancer are undermined by harms from unnecessary prostate biopsy and overdiagnosis of indolent disease. Objective: To evaluate the a priori primary hypothesis that combined measurement of PCA3 and TMPRSS2:ERG (T2:ERG) RNA in the urine after digital rectal examination would improve specificity over measurement of prostate-specific antigen alone for detecting cancer with Gleason score of 7 or higher...
August 1, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28489592/diagnostic-significance-of-urinary-long-non-coding-pca3-rna-in-prostate-cancer
#19
Tao Wang, Xiangyun Qu, Jiajia Jiang, Peng Gao, Dingding Zhao, Xueqi Lian, Xiaohua Li
Prostate cancer antigen 3(PCA3) is a long non-coding RNA, which was found increased expression in CaP patients than healthy individual. In this study, the individual nucleic acid of PCA3 and PSA was recombinant expressed as a reference reagent, and a quantitative RT-PCR with TaqMan assay was developed to examine the copies of PCA3 and PSA gene in urine. The results showed that the area under the receiver operating characteristic curve (AUROC) was 0.717, 0.444 and 0.916 for the number of PCA3 copy, PSA copy and for the score of PCA3/PSA RNA, respectively...
April 20, 2017: Oncotarget
https://www.readbyqxmd.com/read/28485411/prostate-cancer-pca3-as-a-grade-reclassification-predictor
#20
Annette Fenner
No abstract text is available yet for this article.
July 2017: Nature Reviews. Urology
keyword
keyword
17649
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"